Jefferies analyst Roger Song initiated coverage of Sana Biotechnology (SANA) with a Buy rating and $7 price target Sana is a clinical stage biotech focused on bringing engineered cells as medicines to market by leveraging its proprietary hypo-immune editing platform, the analyst tells investors in a research note. The firm says the company has three assets in development for three different disease spaces. It models peak adjusted revenues of $2.8B.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SANA:
- Sana Biotechnology options imply 6.3% move in share price post-earnings
- Short Report: Bears test AI ‘nuclearization’ thesis, add to Oklo shorts
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue